Is This NYSE Ready To Burst Onto The Scene?

Backed By Key Triggered Technical Indicators, Actinium Pharmaceuticals, Inc. (ATNM) Is A Biopharma Company To Get On Radar Immediately Advertisement | [Unsubscribe]( Dear Warrior, It’s Monday evening. Football is on the television. You’re ready to kick up and relax. Well, I’m here to stop you. Instead, it’s time to turn your complete attention to Actinium Pharmaceuticals, Inc. (ATNM). Why? Let me explain. There is demand for a leukemia cure...and the market looks lucrative. The [leukemia therapeutics market]( could reach $17.1Bn by 2024 up from $12.3Bn in 2019, at a CAGR of 6.8%. Do you know what’s driving this market? A rising prevalence of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML). [Grab The Full ATNM Company Report Here.]( Some must also contend with relapsed, or recurrent, [acute myelogenous leukemia (AML)]( which means leukemia came back after treatment and after reaching remission. Refractory AML means leukemia did not respond to treatment. Complete remission can’t be achieved because chemotherapy wasn’t able to kill off enough leukemia cells. The increasing number of approvals of novel and innovative drugs and immunotherapies is evidence of an increasing need for leukemia therapies. Say hello to a wide-open opportunity for Actinium Pharmaceuticals (ATNM). Product Pipeline: Iomab-B (Phase 3) Iomab-B is currently being studied in the pivotal Phase 3 SIERRA (Study of Iomab-B in Elderly Relapsed or Refractory AML) trial, a 150-patient, randomized controlled clinical trial in patients with relapsed or refractory acute myeloid leukemia (AML) who are age 55 and above. Patient enrollment in the SIERRA trial was completed in the third quarter of 2021 and the last patient on SIERRA was transplanted in the fourth quarter of 2021. [Grab The Full ATNM Company Report Here.]( And according to this recent press release, (ATNM) appears to be nearing some Q4 topline data. Check it out: Actinium Pharmaceuticals Announces Iomab-B SIERRA Trial Database Lock, Provides Corporate Update Highlighting Key Upcoming Milestones On track to report topline data from the Pivotal Phase 3 SIERRA trial for Iomab-B in Q4 2022 Overall survival data from the Actimab-A CLAG-M combination trial expected in Q4 2022 Additional updates on collaborations and pipeline progress demonstrating Actinium's leadership in the development of Actinium-225-based radiotherapies expected by year-end Approximately $116Mn in cash and cash equivalents at the end of Q2 2022 expected to fund key value creating clinical, regulatory and R&D milestones through mid-2025 NEW YORK, Sept. 21, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies, today provided a business update and outlook, highlighting upcoming clinical milestones. Key milestones expected before year-end include: topline results for the pivotal Phase 3 SIERRA trial for Iomab-B; survival data from the Actimab-A CLAG-M trial; and additional updates related to progress with the Company's collaborations and internal research programs. "Actinium is on track to deliver topline clinical results from our pivotal Phase 3 SIERRA trial for Iomab-B in the fourth quarter of this year. Iomab-B represents a potential paradigm change in the way difficult to treat relapsed or refractory (r/r) acute myeloid leukemia (AML) patients with active disease can be treated with a potentially curative bone marrow transplant (BMT)," said Sandesh Seth, Chairman and CEO of Actinium. "Iomab-B enables elderly AML patients who are relapsed or refractory to current therapies access to a bone marrow transplant without being in remission whereas current conditioning regimens require patients to be in remission. If successful, SIERRA trial results will demonstrate both improved access and outcomes in transplanted patients who currently survive just a few months as they are not treatable with currently available drugs and cannot be transplanted. Over time, Iomab-B which has been tested in multiple, hard-to-treat blood cancers, has the potential to become a universal conditioning regimen that can improve access and outcomes compared to current non-targeted conditioning regimens for hematological malignancies." … [Read the full article here.]( Could this upcoming data become the catalyst to provide (ATNM) with a breakout spark? ----- Strong Analyst Coverage - Price Targets Galore Chew on this for a second: [Source]( This is saying something when you consider that ATNM was trading in the $7.00 range only 3 weeks ago... And has already exploded to a high of $15.12. But the fireworks are only just beginning... [Grab The Full ATNM Company Report Here.]( HC Wainwright analyst, Joseph Pantginis, has even tagged ATNM with a $45.00 target that gives ATNM over 444% potential upside from Thursday’s close. Now, do we expect ATNM to go surging to any of those price target levels in the near term? No. But, with 4 targets nearly 100% higher than its current trading levels paints the portrait of a profile that may be significantly undervalued at this very moment. ----- Low Float - Strong Potential For Volatility ATNM is a low float profile. With [Yahoo Finance]( reporting it to have around 24.29Mn shares in its float, volatility could pop up at any moment. This is important for one key reason. If a low float company is able to produce good news, there are so few shares available for trading that sharp price spikes (volatility) can become a reality. So with Q4 topline data right around the corner, who knows what could be at stake for ATNM in the near term. ----- Coverage is officially initiated on Actinium Pharmaceuticals (ATNM). Make sure to get it on your radar before Friday’s opening bell. Be in touch soon. Benjamin Bull Editor, Wall St. Warrior Wall St. Warrior (wallstwarrior.com) and Dollar Stock Club (dollarstockclub.com) are owned by Guardian Financial Publishing LLC, a limited liability company. Disclosure: I am not a fin-an-cial adviser. All potential percentage gains are based on from the low to the high of day. Wall St. Warrior and Dollar Stock Club full disclosure is to be read and fully understood before using Wall St. Warrior and Dollar Stock Club website, or joining Wall St. Warrior and Dollar Stock Clubs’ email or text list. By viewing Wall St. Warrior and Dollar Stock Club website and/or reading Wall St. Warrior and Dollar Stock Clubs email or text newsletter you are agreeing to Wall St. Warrior and Dollar Stock Club’s full disclosure which can be read at Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Wall St. Warrior (wallstwarrior.com) and Dollar Stock Club (dollarstockclub.com) is owned by Guardian Financial Publishing LLC, a limited liability company. Pursuant to an agreement between Guardian Financial Publishing LLC and TD Media Media LLC, Guardian Financial Publishing LLC has been hired for a period beginning on 11/07/2022 and ending on 11/09/2022 to publicly disseminate information about (ATNM:US) via digital communications. We have been paid an additional ten thousand dollars USD via bank wire transfer. To date we have been paid ten thousand dollars USD via bank wire transfer to disseminate information about (ATNM:US) via digital communications. We own zero shares of (ATNM:US). Guardian Financial Publishing 3571 Far West Blvd Austin, TX 78731 United States This email was sent to {EMAIL}. Don't want to receive these emails anymore? [Unsubscribe]( [Privacy Policy]( | [Terms]( | [Risk Disclosure](